Mizuho has upgraded Belite Bio Inc (BLTE) to Outperform from Neutral as of December 1, 2025. This change reflects a more optimistic outlook on the company's prospects.
Belite Bio, headquartered in San Diego, California, specializes in the research and development of drugs targeting retinal degenerative diseases and metabolic conditions. The firm has a market capitalization of $3.6 billion and reported a trailing twelve-month EPS of -1.52. Its lead product candidate, Tinlarebant, is an oral treatment for patients with Stargardt disease type 1 and geographic atrophy, both of which can lead to blindness.
Analyst consensus indicates a Buy rating, with 3 Strong Buy, 7 Buy, 2 Hold, and no Sell or Strong Sell ratings among 12 total analysts. Upcoming earnings are projected for May 11, 2026, with an EPS estimate of -0.48 and no revenue expected. The recent upgrade underscores a shift in sentiment, potentially due to improved fundamentals or better-than-expected performance.
Analyst ratings serve as professional opinions based on research and financial models. While they offer valuable insights, they should not be the sole basis for investment decisions. Investors are advised to consider various factors, including company fundamentals and market conditions, when making choices.